Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05114343
Other study ID # THE_JIA study
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 2021
Est. completion date April 2024

Study information

Verified date August 2021
Source University of Sao Paulo General Hospital
Contact Tiago Peçanha, PhD
Phone +5511948243542
Email tiagopecanha@usp.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will aim to test the effectiveness and feasibility of a technology-supported home-based exercise program in adolescents with JIA. For this, adolescents (< 18 years) with JIA will be randomized to a 12-weeks home-based exercise program or usual care (i.e., no exercise control intervention). The home-based exercise intervention will be delivered remotely using a video calling app, and participants will be instructed to perform 3 sessions of weight-bearing exercise per week. Participants will be supported by educational materials, a heart rate monitor, and through periodic contact with an exercise specialist via video and phone calls, and text messages. The study's primary outcomes will be: cardiac and vascular function and structure using ultrasound imaging, body composition (DXA), aerobic capacity, muscle strength and functional capacity. In addition to that, the feasibility, safety, acceptability, and barriers and facilitators to the intervention will also be assessed.


Description:

Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and adolescents under the age of 16. In addition to the articular features of the disease, JIA is also characterized by multiple comorbidities, including cardiovascular manifestations. Part of the health conditions observed in adolescents with JIA may be caused by a reduced practice of physical activity. Lack of physical activity in this disease has been attributed to generic and specific barriers, such as time constraints, low motivation, limited access to specialized exercise centers, lack of specific programs for JIA patients, among others. More recently, the COVID-19 pandemic has imposed additional challenges for the engagement in physical activity in populations with chronic disease, including patients with JIA. In this scenario, home-based exercise programs supported by technology have arisen as potentially effective alternatives to upregulate physical activity levels in adolescents with JIA, which needs to be further explored. Therefore, the aim of this study will be to test the effectiveness and feasibility of a technology-supported home-based exercise program in adolescents with JIA. For this, adolescent (< 18 years) patients with JIA will be randomized to a 12-weeks home-based exercise program or usual care (i.e., no exercise control intervention). The home-based exercise intervention will be delivered remotely using a video calling app, and participants will be instructed to perform 3 sessions of weight-bearing exercise per week. Exercise intensity and duration will be low-to-moderate in the first 4 weeks, and will progressively increase during the program. Participants will be supported by educational materials, a heart rate monitor, and by means of periodic contact with an exercise specialist via video and phone calls, and text messages. Participants in the control group will receive usual care and general instructions about physical activity. The study's primary outcome will be the cardiac and vascular structure and function assessed by vascular ultrasound imaging, body composition (DXA), aerobic capacity, muscle strength and functional capacity. Secondary outcomes will include clinical aspects of the disease, blood parameters, physical activity and sedentary behavior, food consumption, health-related quality of life, blood pressure, and cardiac autonomic function. Feasibility, safety, acceptability, and barriers and facilitators to the intervention will also be evaluated. The effects of the intervention on study outcomes will be assessed by a mixed model analysis (p < 0.05).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date April 2024
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 10 Years to 18 Years
Eligibility Inclusion Criteria: - Patients with polyarticular or oligoarticular subtypes of juvenile idiopathic arthritis. Exclusion Criteria: - Cardiovascular, metabolic, pulmonary or renal diseases - Untreat thyroid disease - Blood pressure > 140/80 mmHg - Use of statin - Use of tobacco - Any other disease or condition that may prevent the practice of physical activity

Study Design


Intervention

Behavioral:
Exercise
Participants will perform weight-bearing exercises for 12 weeks. The intervention will be delivered remotely through video calling with an exercise specialist.

Locations

Country Name City State
Brazil Hospital das Clínicas da Faculdade de Medicina da USP - HCFMUSP Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Endothelial function Endothelial function will be assessed through the evaluation of brachial flow-mediated dilation using a vascular ultrasound. Change from baseline to 12 weeks
Primary Cardiac chamber dimensions (left ventricle diastolic and systolic diameters, interventricular septum, left ventricular posterior wall) Left ventricle diastolic and systolic diameters, interventricular septum, and left ventricular posterior wall in millimeters per meter squared will be assessed using standard echocardiography. Change from baseline to 12 weeks
Primary Left ventricular ejection fraction (LVEF) Left ventricular ejection fraction (LVEF) in percentage will be assessed using standard echocardiography. Change from baseline to 12 weeks
Primary Left ventricular mass index The left ventricular mass index in grams per body surface area will be assessed using standard echocardiography. Change from baseline to 12 weeks
Primary Left ventricular diastolic function Left ventricular diastolic function will be assessed using tissue Doppler-based measurements of transmitral E and A velocities in metre per second. Change from baseline to 12 weeks
Primary Myocardial deformation Myocardial deformation in longitudinal, radial, and circumferential directions will be assessed using two-dimensional speckle-tracking (2DST) echocardiography and expressed as a percentage. Change from baseline to 12 weeks
Primary Body fat Body fat in % will be assessed using dual-energy X-ray absorptiometry. Change from baseline to 12 weeks
Primary Lean mass Lean mass in kilograms will be assessed using dual-energy X-ray absorptiometry. Change from baseline to 12 weeks
Primary Bone mineral content Bone mineral content in grams will be assessed using dual-energy X-ray absorptiometry. Change from baseline to 12 weeks
Primary Aerobic fitness Aerobic fitness will be assessed through a graded treadmill exercise test. VO2max will be assessed using a metabolic cart and expressed in millilitres per kilograms of body weight. Change from baseline to 12 weeks
Primary Vascular structure Vascular structure will be assessed through the analysis of common carotid intima-media thickness using a vascular ultrasound. Change from baseline to 12 weeks
Primary Feasibility of the intervention Feasibility of the intervention will be assessed through interviews investigating the experiences of the participants during the intervention. Change from baseline to 12 weeks
Primary Adherence to the intervention The adherence to the intervention will be assessed using the data from the physical activity diaries and heart rate monitor and will be expressed as percentage of complete sessions. Change from baseline to 12 weeks
Secondary Disease activity Participants' disease activity will be calculated using the Juvenile Arthritis Disease Activity Score. Change from baseline to 12 weeks
Secondary Disease activity Participants' disease activity will be calculated using the Juvenile Arthritis Disease Activity Score. Change from baseline to 24 weeks
Secondary Functional ability The functional ability of the participants with JIA will be assessed through the Brazilian-Portuguese version of the Childhood Health Assessment Questionnaire (CHAQ). Change from baseline to 12 weeks
Secondary Functional ability The functional ability of the participants with JIA will be assessed through the Brazilian-Portuguese version of the Childhood Health Assessment Questionnaire (CHAQ). Change from baseline to 24 weeks
Secondary Health-related quality of life Health-related quality of life will be assessed through the Pediatric Quality of Life Inventory (PedsQL). Change from baseline to 12 weeks
Secondary Health-related quality of life Health-related quality of life will be assessed through the Pediatric Quality of Life Inventory (PedsQL). Change from baseline to 24 weeks
Secondary Cardiometabolic blood markers The following cardiometabolic markers from blood will be assessed after 12-h fasting: blood glucose and insulin, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, and triglycerides. This data will be expressed in milligrams per deciliter. Change from baseline to 12 weeks
Secondary C-reactive protein C-reactive protein levels in the blood will be assessed after 12-h fasting and expressed as milligrams per litre. Change from baseline to 12 weeks
Secondary Physical activity and sedentary behavior Physical activity and sedentary behavior will be assessed using a thigh-worn accelerometer (activPAL). Change from baseline to 12 weeks
Secondary Physical activity and sedentary behavior Physical activity and sedentary behavior will be assessed using a thigh-worn accelerometer (activPAL). Change from baseline to 24 weeks
Secondary Motivation to physical activity Motivation to physical activity will be assessed using the Behavioral Regulation in Exercise Questionnaire-2 (BREQ-2). Change from baseline to 12 weeks
Secondary Physical activity-related behavior Physical activity-related behavior will be asseessed using the Stages of Change model. Change from baseline to 12 weeks
Secondary Food consumption Food consumption will be assessed through 24-hour food recalls, collected on three non-consecutive days (one weekend day). Change from baseline to 12 weeks
Secondary Blood pressure Blood pressure (arterial pressure) will be assessed non-invasively using a multi-parameter monitor. Change from baseline to 12 weeks
Secondary Cardiac autonomic function Cardiac autonomic function will be assessed through the analysis of heart rate variability, which will be recorded using a heart rate monitor. Change from baseline to 12 weeks
Secondary Muscle strength Muscle strength will be assessed by the one-repetition maximum test on the bench press and knee extension machines and will be expressed as kilograms. Change from baseline to 12 weeks
Secondary Muscle strength Muscle strength will be assessed by the one-repetition maximum test on the bench press and knee extension machines and will be expressed as kilograms. Change from baseline to 24 weeks
Secondary Handgrip strength Handgrip strength will be assessed using handgrip dynamometry and expressed as kilograms. Change from baseline to 12 weeks
Secondary Handgrip strength Handgrip strength will be assessed using handgrip dynamometry and expressed as kilograms. Change from baseline to 24 weeks
Secondary Functional capacity - Timed-Stands Functional capacity will be assessed using the "Timed-Stands" test and expressed by the number of sit-to-stand repetitions. Change from baseline to 12 weeks
Secondary Functional capacity - Timed-Stands Functional capacity will be assessed using the "Timed-Stands" test and expressed by the number of sit-to-stand repetitions. Change from baseline to 24 weeks
Secondary Functional capacity - Timed Up-And-Go Functional capacity will be assessed busing the "Timed Up-And-Go" test and expressed in seconds. Change from baseline to 12 weeks
Secondary Functional capacity - Timed Up-And-Go Functional capacity will be assessed busing the "Timed Up-And-Go" test and expressed in seconds. Change from baseline to 24 weeks
See also
  Status Clinical Trial Phase
Completed NCT02776735 - An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Phase 2
Active, not recruiting NCT03092427 - Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) N/A
Not yet recruiting NCT05545098 - MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
Not yet recruiting NCT03833609 - Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis N/A
Completed NCT02524340 - Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
Recruiting NCT01434082 - Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis N/A
Completed NCT04671524 - The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected N/A
Recruiting NCT04167488 - Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy N/A
Recruiting NCT04205500 - Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis N/A
Terminated NCT01694264 - Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα Phase 3
Completed NCT02824978 - Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
Active, not recruiting NCT03841357 - Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Phase 3
Completed NCT03833271 - The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary Early Phase 1
Completed NCT01455701 - A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 1
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT01436019 - Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis N/A
Recruiting NCT05609630 - Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Phase 3
Recruiting NCT05696340 - Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05436301 - Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)